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Abstract
Telomeres are protective repeats of TTAGGG sequences located at the end of human chro-
mosomes. They are essential to maintain chromosomal integrity and genome stability. Telo-
merase is a ribonucleoprotein complex containing an internal RNA template (hTR) and a
catalytic subunit (hTERT). The human hTR gene consists of three major domains; among
them the H/ACA domain is essential for telomere biogenesis. H/ACA ribonucleoprotein
(RNP) complex is composed of four evolutionary conserved proteins, including dyskerin
(encoded by DKC1 gene), NOP10, NHP2 and GAR1. In this study, we have evaluated the
expression profile of the H/ACA RNP complex genes: DKC1, NOP10, NHP2 and GAR1, as
well as hTERT and hTR mRNA levels, in patients with chronic lymphocytic leukemia (CLL).
Results were correlated with the number and type of genetic alteration detected by conven-
tional cytogenetics and FISH (fluorescence in situ hybridization), IGHV (immunoglobulin
heavy chain variable region) mutational status, telomere length (TL) and clinico-pathological
characteristics of patients. Our results showed significant decreased expression of GAR1,
NOP10, DKC1 and hTR, as well as increased mRNA levels of hTERT in patients compared
to controls (p0.04). A positive correlation between the expression of GAR1-NHP2, GAR1-
NOP10, and NOP10-NHP2 (p<0.0001), were observed. The analysis taking into account
prognostic factors showed a significant increased expression of hTERT gene in unmutated-
IGHV cases compared to mutated-CLL patients (p = 0.0185). The comparisons among
FISH groups exhibited increased expression of DKC1 in cases with two or more alterations
with respect to no abnormalities, trisomy 12 and del13q14, and of NHP2 and NOP10 com-
pared to those with del13q14 (p = 0.03). The analysis according to TL showed a significant
increased expression of hTERT (p = 0.0074) and DKC1 (p = 0.0036) in patients with short
telomeres compared to those with long TL. No association between gene expression and
clinical parameters was found. Our results suggest a role for these telomere associated
genes in genomic instability and telomere dysfunction in CLL.
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Introduction
Telomeres are protective repeats of TTAGGG sequences located at the end of chromosomes
[1]. One important function of the telomere is to prevent end-to-end joining of chromosomes,
which otherwise could lead to the accumulation of chromosomal breaks during mitosis. Due
to the end-replication problem, telomeres become progressively shorter with repeated cell
division. Telomere shortening leads to telomere dysfunction and elicitation of a DNA damage
response. Moreover, it has implications in oncogenesis and cellular aging due to limited cellu-
lar proliferation below a certain critical telomere length (TL) [2].
TL is maintained by the enzymatic complex telomerase. This enzyme participates in the for-
mation and maintenance of telomeres in normal progenitor cells [3] and is active in most of
tumors and immortal cell lines, endowing cancer cells with an infinite replicative capacity [4,
5]. Telomerase consists of two core components: a catalytic subunit, human telomerase reverse
transcriptase (hTERT) with reverse transcriptase activity and a RNA component, human telo-
merase RNA component (hTR) that serves as a template for the elongation of telomeres. As
described in detail previously [6] human hTR extends for 451 nucleotides, the last 240 at the 3
´end form a consensus H/ACA two hairpin structure while the 5’ half folds into a pseudoknot
containing the template for the reverse transcriptase. While it is not needed for telomerase
activity in vitro, the H/ACA domain of hTR is required for its in vivo accumulation and stabil-
ity [6, 7]. Telomerase activity requires additional ribonucleoprotein (RNP) factors that associ-
ate with hTERT and hTR to form the holoenzyme. Thus, H/ACA RNPs consist of four
evolutionarily conserved proteins, Dyskerin [encoded by the gene DKC1 (Dyskerin Pseudouri-
dine Synthase 1)], NHP2 (NHP2 ribonucleoprotein), NOP10 (NP10 ribonucleoprotein), and
GAR1 (GAR1 ribonucleoprotein), and a function-specifying, noncoding H/ACA RNAs [8, 9].
All these RNPs are concentrated in nucleoli and Cajal bodies of mammalian cells, reflecting
the location of H/ACA RNPs [10]. In reference to its functions, H/ACA RNPs contribute to
telomerase assembly and stabilization, posttranscriptional processing of nascent ribosomal
RNA and pre-mRNA splicing [6]. Dyskerin, NHP2 and NOP10 are essential for the cellular
accumulation of the H/ACA-motif RNAs, while GAR1 binds only to Dyskerin and is necessary
for the nucleolar localization and function of the RNP complex [11, 12]. Particularly, Dyskerin
functions as a pseudouridine synthase and is involved in post-transcriptional modifications of
rRNA [13]. In addition, Dyskerin is part of the telomerase complex and is required for the
correct activity of the enzyme, which directly binds to and stabilizes hTR within the complex
[14], playing a role in the maintenance of telomere integrity. Point mutations in DKC1 gene
cause the X-linked form of dyskeratosis congenital, a disease with increased predisposition to
cancer.
Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in adults in Western
countries; it is a heterogeneous disease with variable clinical presentation and evolution [15].
At the molecular level, two major subtypes can be distinguished, mutated (M) and unmutated
(UM), characterized respectively by a high or low number of somatic hypermutations in the
variable region of immunoglobulin genes and different clinical evolution [16, 17]. Cytogenetic
and FISH (fluorescence in situ hybridization) studies have also proved to be important tools in
the biologic characterization of this disease, allowing the identification of distinct cytogenetic
risk groups and providing information for clinical outcome [18, 19]. In addition, short telo-
meres have been associated with genetic complexity and a high risk of genomic aberrations
[20–23], and ultimately implicated in disease outcome [21, 22, 24]. Increased telomerase
expression and activity were also observed in CLL patients [25, 26]. However, data concerning
the participation of H/ACA RNPs in telomere dysfunction in CLL are lacking. In the present
study, we investigated the expression profile of DKC1, NHP2, NOP10 and GAR1, in association
H/ACA RNP expression in CLL
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with hTR and hTERT mRNA levels. Results were correlated with the number and type of
genetic alterations detected by conventional cytogenetics and FISH, the mutational status of
IGHV (immunoglobulin heavy chain variable region), TL and clinico-pathological characteris-
tics of patients.
Materials and methods
Patients
This study was based on a retrospective series of 71 CLL patients at diagnosis (31 females;
mean age 67 years, range: 44–88 years) derived to our Laboratory from 2006 to 2016, and from
whom RNA samples were available. Patients were diagnosed according to the National Cancer
Institute-Working Group CLL criteria [27]. Rai stages [28] were available for 54 cases with the
following distribution: 0: 19 (35.2%); I–II: 30 (55.5%); and III–IV: 5 (9.3%). Table 1 shows clin-
ical and biological characteristics of patients. In addition, 21 normal controls (NC) (without a
medical history of cancer) (10 females; mean age 62 years, range: 40–89 years), were properly
selected to this study. The study was approved by the Ethics Committee of the Institutes of the
National Academy of Medicine of Buenos Aires (Approval number: T.I.N˚ 12042/15/X). All
patients provided their written informed consent.
RNA extraction and reverse transcription (RT)
Total RNA was extracted from mononuclear cells isolated on a Ficoll-Paque Plus (GE Health-
care Bio-Sciences) density gradient of peripheral blood (PB) samples of patients, normal con-
trols (NC) and the K-562 cell line, using the Trizol reagent. K-562 cell line was obtained from
the Laboratory of Genetics in Hematology, Institute of Experimental Medicine, CONICET-
National Academy of Medicine (Buenos Aires, Argentina). The complementary DNA (cDNA)
synthesis was carried out by using Moloney Murine Leukemia Virus reverse transcriptase
(MMLV) and random primer (Promega). The cDNA synthesis was performed in a final vol-
ume of 20 μl, containing 1μg of the total RNA, for 10 minutes at 70˚C, for 60 minutes at 37˚C
and 10 minutes at 95˚C to inactive the enzyme. cDNA was stored at -20˚C until use.
Table 1. Clinical and biological characteristics of CLL patients.
Characteristics
N˚ of patients (n) 71
Sex F/M 31/41
Mean age (years) (range) 67 (44–88)
Clinical stages (%)
Rai 0 19 (35.2)
Rai I–II 30 (55.5)
Rai III–IV 5 (9.3)
Mean WBC count (×109/L) (range) 41.4 (9.1–210)
Mean lymphocyte (%) (range) 76.1 (15.5–97)
Mean Plt count (×109/L) (range) 212.3 (67–900)
Mean Hb (g/dL) (range) 12.5 (7–15.9)
Mean LDH (UI/L) (range) 380 (128–647)
Mean β2M (μg/mL) (range) 2.77 (0.37–8)
F: female, M: male, WBC: white blood cells, Plt: platelets, Hb: hemoglobin, LDH: lactate dehidrogenase,
β2M: β2-microglobulin.
https://doi.org/10.1371/journal.pone.0179883.t001
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Gene expression analysis by quantitative real-time RT-PCR
The analysis of four genes of the RNP complex GAR1, NHP2, NOP10 and DKC1, as well as
both telomerase units, hTR and hTERT, were performed using real-time quantitative PCR
(qPCR) on a Rotor GENE Q (Qiagen), based on SybrGreen methodology. Primer sequences
for hTR and hTERT were previously described [29, 30]. For the remaining genes, primers were
designed for this work and detailed in Table 2. All PCR runs were performed in duplicate,
using 2.5 μl of RT reaction, 2X SYBR1 Select Master Mix (Applied Biosystems1), 10 mM of
each primer, in a 20 μl final volume.
The constitutive expression gene β-Actin was used to normalize sample-to-sample differ-
ences in cDNA input, RNA quality and RT efficiency [31]. For all targets, the thermal cycling
conditions were 2 minutes at 50˚C, followed by 2 minutes at 95˚C; continued by 45 cycles at
95˚C for 20 seconds and 60˚C for 1 minute, ending with a melting curve from 50˚C to 99˚C.
All measurements included a determination of the standards and no-template as a negative
control, in which water was substituted for the cDNA. Standard curves were constructed with
fivefold serial dilutions of the cDNA from the K-562 cell line.
Cytogenetics and FISH analysis
Chromosome analyses were performed on PB lymphocytes, cultured for 96 h at 37˚C in F-12
medium supplemented with 15% of fetal calf serum, stimulated with Pokeweed mitogen. Slides
were prepared by conventional method. G-banding technique was used. For FISH analysis,
slides were hybridized with SE 12, OLE13q14 D13S319, OLE11q22.3 ATM, and 17p13.1 TP53
DNA probes (LiVE-LEXEL, Buenos Aires, Argentina) according to the manufacturer’s proto-
col. Two hundred interphase nuclei were analyzed for each probe. The cut-offs for positive val-
ues (mean of normal control plus 3 standard deviations) determined from ten cytogenetically
normal donors were as follows: 3%, 10%, 7.5%, and 5.5% for trisomy 12, monosomies of
D13S319, ATM, and TP53, respectively.
Table 2. Primer sequences.
Name of primer Sequence (5’– 3’) Length (pb) Reference
β-actin F CCAGAGGCGTACAGGGATAG 97 [32]
β-actin R CCAACCGCGAGAAGATGA
hTR F TCTAACCCTAACTGAGAAGG 126 [30]
hTR R GTTTGCTCTAGAATGAACGG
hTERT F TGACACCTCACCTCACCCAC 95 [31]
hTERT R CACTGTCTTCCGCAAGTTCAC
NOP10 F TTCGGACTGTGAGCCCTGATGCCTTT 70 Designed in this study
NOP10 R TCAATCGCCACGAGAGACTGGATGCC
NHP2 F CTTCTGTCCATCAGTGCCAT 105 Designed in this study
NHP2 R AGCATTTACTTTCCCCACCC
DKC1 F TGAAGAGAGAGATTGGGGACT 85 Designed in this study
DKC1 R ATGGGAAGAGGGGTTAGAGG
GAR1 F CGGAGGTCGTGGAGGCTTT 77 Designed in this study
GAR1 R CTCGGAAGTGGTTGCTGCTG
F: forward; R: reverse.
https://doi.org/10.1371/journal.pone.0179883.t002
H/ACA RNP expression in CLL
PLOS ONE | https://doi.org/10.1371/journal.pone.0179883 June 30, 2017 4 / 13
Absolute telomere length analysis
High-molecular weight genomic DNA was obtained from PB mononuclear cells of CLL
patients and controls, separated on a Ficoll-Paque Plus (GE Healthcare Bio-Sciences, Uppsala,
Sweden) density gradient. Absolute TL measurement was carried out by real-time quantitative
PCR (qPCR) in a LightCycler system (Roche Diagnostics) according to Panero et al. [32]. For
each DNA sample, two consecutive reactions were performed: the first one to amplify a single
copy gene, RPLP0 (ribosomal protein lateral stalk subunit P0) (12q24.2), and the second one
for telomeric sequence. Briefly, both PCRs were performed in a final volume of 20 μl using 1X
SYBRGreen Master Mix (Roche), 100 nmol/L of primers, and 20 ng of DNA from patients and
controls. The PCR conditions were as follows: 95˚C 10 min, followed by 45 cycles of 95˚C 15 s,
60˚C 1 min. The melting curve was performed with 1 cycle of 95˚C 20 s, 50˚C 15 s, and 98˚C
with a temperature ramp of 0.1˚C/s. All samples were analyzed in duplicate. Absolute TL
(kb/diploid genome) values were calculated as previously described [33]. The conversion of
absolute TL values into the equivalent Southern blot TL values (kb) was done by using the
regression formula: y = 0.0746x + 0.5285, where x = Log [TL (qPCR)] and y = Log [TL (TRF)]
as was previously explained [243].
IGHV mutational status
The IGHV gene sequences were determined as previously described [34]. Briefly, amplifica-
tion of IGHV regions by polymerase chain reaction was performed on cDNA by using VH
framework region 1 consensus family specific primers (VH1-VH6) and JH primers. When
amplifications of these primers were unsuccessful, an alternative set of primers that anneal to
sequences in the leader region (LH1-LH6) and one antisense Cμ-primer were used. Thermal
cycling conditions were 3 minutes at 93˚C, followed by 33 cycles at 94˚C for 30 seconds,
62˚C for 30 seconds, 72˚C for 30 seconds, elongation at 72˚C for 7 minutes, and a final step
at 4˚C for 10 minutes. Polymerase chain reaction products were purified in 2% agarose gels,
sequenced bidirectionally, and analyzed on an automated DNA sequence analyzer (377 ABI
Prism, PE biosystem, Foster City, CA). Sequence data were analyzed by using IgBLAST
(immunoglobulin BLAST) (http://www.ncbi.nlm.nih.gov/igblast) and the ImMunoGeneTics
database (IMGT) (http://imgt.cines.fr). IGHV sequences with <98% homology with respect
to the germ line counterpart were considered as M, whereas those with homology of 98% or
higher were classified as UM [17, 18].
Statistical analysis
Statistical analysis was performed using GraphPad Prism Version 5.0 (2008). Comparisons of
data from patients and controls were performed using the Mann-Whitney test meanwhile
Kruskal-Wallis test was used for comparisons among subgroups. Groupwise comparison of
the distribution of clinical and laboratory variables was performed with the Student t test (for
quantitative variables) and the χ2 or Fisher’s exact test (for categorical variables). Correlations
between gene expression and TL or clinical variables were assessed by using the Kendall’s coef-
ficient. The cut-off point for gene expression was selected according to receiver operating
characteristic (ROC) analysis. A hierarchical clustering was employed to segregate patients
groups based on the qPCR expression patterns using the Heatmapper (www.heatmapper.ca).
Treatment free survival (TFS), calculated from the date of diagnosis to the first CLL-specific
treatment were estimated by the Kaplan-Meier method and compared with the Log-rank test.
For all tests, p<0.05 was considered statistically significant.
H/ACA RNP expression in CLL
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Results
Expression profile of RNP complex genes and telomerase subunits
The expression profile of the four RNP complex genes: GAR1, NHP2, NOP10 and DKC1, as
well as the two subunits of telomerase, hTR and hTERT, were evaluated in 71 CLL patients and
21 NC. The analysis showed a decreased expression of RNP complex genes in CLL patients
compared to NC, with significant differences for: GAR1 (p = 0.0156), DKC1 (p = 0.0025) and
NOP10 (p = 0.0048). No statistical differences were found for NHP2 mRNA expression
(p = 0.182) (Fig 1A). In reference to telomerase subunits, an increase of hTERT (p = 0.0441)
and a decrease of hTR (p = 0.0005) in patients compared to NC were observed (Fig 1B). In
addition, a positive correlation between the expression of GAR1-NHP2,GAR1-NOP10, and
NOP10-NHP2 (p<0.0001) were found, indicating a strong interaction among them (Support-
ing information; S1 Fig). A more integrative vision of telomere-associated gene expression
profiles can be observed in Supporting information (Heat map; S2 Fig).
Correlation between expression profiles and prognostic factors in CLL
We would like to determine if the expression profile of these genes correlated with prognostic
factors of relevance in CLL. Thus, we analyzed the association between transcription levels and
Fig 1. Gene expression profiles in CLL patients and normal controls (NC). (A) GAR1, NHP2, DKC1 and
NOP10 genes. (B) hTR and hTERT genes.
https://doi.org/10.1371/journal.pone.0179883.g001
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different parameters, including the number and type of genetic alterations detected by conven-
tional cytogenetics and FISH, the mutational status of IGHV, TL and clinico-pathological char-
acteristics of patients.
IGHV mutational status was evaluated in 66 cases: 34 showed M-CLL, 31 were UM-CLL
and one case had a stop codon. Expression analysis of telomerase genes according to this
parameter revealed significant increased expression of hTERT gene in UM-CLL patients
(p = 0.0185) compared to M-CLL (Fig 2).
Cytogenetic and/or FISH analysis were performed in 56 patients. Eight cases had two or
more cytogenetic alterations in the karyotype, 14 showed normal karyotype and no FISH alter-
ations, 14 had del13q14 as the only abnormality, 7 cases showed trisomy 12, and the remaining
13 had two or more FISH alterations. No differences in gene expression profiles between patients
with two or more alterations by cytogenetics and FISH analysis were found, thus they were con-
sidered as a single group (2 or more CA). The analysis among groups showed significant differ-
ences for DKC1 (p = 0.0028) and hTR (p = 0.0129) and a tendency for NHP2 (p = 0.057) and
NOP10 (p = 0.068). Interestingly, when risk genetic groups were compared, an increased expres-
sion of DKC1 in cases with 2 or more CA with respect to those with no abnormalities (NA)
(p = 0.0120), trisomy 12 (p = 0.0362) and del13q14 (p = 0.0304) (Fig 3A), was observed. More-
over, overexpression of NHP2 and NOP10 genes in patients with 2 or more CA compared to
those with del13q14 (p = 0.003 and p = 0.0375, respectively) were also found (Fig 3B and 3C).
Fig 2. Increased expression of hTERT gene in unmutated (UM)-CLL patients compared to mutated
(M)-CLL.
https://doi.org/10.1371/journal.pone.0179883.g002
H/ACA RNP expression in CLL
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TL was measured in 32 patients of our cohort. Short telomeres were defined as below the
tenth percentile of normal controls (6.63 Kb). Twelve cases had short TL and 20 showed long
TL. This analysis showed a significant increased expression of hTERT (p = 0.0074) and DKC1
(p = 0.0036) in patients with short telomeres compared to those with long TL. In contrast, the
remaining genes did not showed significant differences (Fig 4).
Finally, the analysis taking into account clinico-pathological characteristics of patients as
well as treatment-free survival and overall survival did not reveal any prognostic relevance
(Supporting information; S1 Table).
Discussion
In the present study, we have analyzed the expression profiles of four genes of the RNP com-
plex GAR1, NHP2, NOP10 and DKC1, as well as both telomerase units, hTR and hTERT, in
CLL patients at diagnosis. It is important to pointing out that, to our knowledge, this is the
first analysis of GAR1, NHP2, NOP10 and hTR in this pathology.
Our results showed significant decreased expression GAR1, NOP10, DKC1 and hTR, as well
as increased mRNA levels of hTERT in CLL patients compared to controls, supporting the
Fig 3. Analysis of gene expression profiles of telomere associated genes taking into account the
number and type of genetic alterations in CLL patients. (A) Significant differences for DKC1 in cases with
two or more chromosome alterations (2 or more CA) with respect to no abnormalities (NA), trisomy 12 and
del13q14. In addition, significant differences between normal controls (NC) and CLL patients with NA
(p = 0.01134), trisomy 12 (p = 0.0274) and del13q14 (p = 0.0081) were observed; (B) Increased expression of
NHP2 in patients with 2 or more CA compared to those with del13q14; (C) Increased expression of NOP10 in
patients with 2 or more CA compared to those with del13q14. Furthermore, significant differences between
NC and del13q14 (p = 0.0115) was observed.
https://doi.org/10.1371/journal.pone.0179883.g003
H/ACA RNP expression in CLL
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importance of changes in the expression of telomere-associated genes in this entity. There is
scarce information about these genes in hematological malignancies. A report of our group
[35] using microarray assay found increased expression of NOP10, GAR1 and NHP2 in mye-
loma cell lines and patients with plasma cell disorders, showing significant overexpression
from monoclonal gammopathy of undetermined significance (MGUS) to plasma cell leuke-
mia, indicating their association with tumor progression. On the contrary, there are some
reports about DKC1 and hTERT expression in CLL. In concordance with our findings, two
studies found decreased expression of DKC1 compared to controls [36, 37]. Sbarrato et al [37]
suggested that the low DKC1 expression leads to an imbalance in ribosomal proteins that
could influence the response of leukemic cells to the microenvironment, and proposed a gen-
eral impact of DKC1 dysregulation on the translational machinery in CLL. Other authors sug-
gest that DKC1 deficiency may contribute to tumorigenesis by altering the splicing of specific
mRNAs, or by modulating the level of certain snoRNAs [13]. In vitro experiments showed that
the loss of DKC1 function affects telomerase activity by reducing hTR levels, leading to prema-
ture telomere shortening that may result in chromosomal end-to-end fusions, breakage and
rearrangements associated to tumor development [13].
In reference to hTERT expression, there are discordant results probably related with the
number of patients and/or the clinical characteristics of the cohorts evaluated. Poncet et al [36]
found hTERT down-regulation and Damle et al [38] did not observed significant differences in
CLL patients compared to controls. On the contrary, Hoxha et al [3926] observed hTERT over-
expression by microarray analysis, data that could not be validated by qRT-PCR. Interestingly,
we found increased hTERT mRNA levels associated to UM-CLL and short TL. Conflicting
results were reported about the association between hTERT mRNA expression and IGHV
mutational status [21, 26, 38–40]. Our data, in concordance with those observed by Rampazzo
et al [22], support the relationship between short TL, UM-IGHV status and increased hTERT
expression in this pathology, as well as the importance of hTERT levels to maintain the replica-
tive potential of tumor cells. In addition, a previous study of our group in patients with multi-
ple myeloma (MM) also showed an inverse correlation between hTERT levels and TL, in
Fig 4. Analysis of hTERT and DKC1 gene expression profiles tacking into account telomere length
(TL). Significant increased expression for hTERT and DKC1 in patients with short TL compared to those with
long TL.
https://doi.org/10.1371/journal.pone.0179883.g004
H/ACA RNP expression in CLL
PLOS ONE | https://doi.org/10.1371/journal.pone.0179883 June 30, 2017 9 / 13
which shortest telomeres had the highest hTERT expression [41]. Furthermore, it is important
to pointing out that, besides maintaining the TL, hTERT is also involved in other cellular func-
tions like cell survival and prevention of apoptosis [42, 43], which would be important to eval-
uate in CLL.
With regards to genomic aberrations, our data showed significantly increased mRNA
levels of DKC1, NHP2 and NPO10 genes in CLL cases with two or more alterations. Using
microarray assay, von Stedingk et al [44] found DKC1, NHP2 and GAR1 overexpression in
high-stage neuroblastoma associated to poor prognosis and genomic complexity, as well as
telomere dysfunction, proposing their relationship with tumor aggressiveness. More studies
will be necessary to clarify the role of these genes in CLL progression. Simultaneously, we
also observed increased DKC1 expression in patients with short TL, supporting the probable
involvement of this gene in progressive telomere reduction, promoting genomic instability
and immortalization of cancer cells. In concordance, a previous report [45] in lung cancer
cells also found a strong association between Dyskerin and short telomeres and more
recently our group showed DKC1 overexpression in MM patients with short TL [46]. In ref-
erence to GAR1, we did not find association with the different prognostic factors evaluated.
A recent report on cell lines [47] found differential expression of this protein in response to
different genotoxic agents and particularly to DNA damage response. The authors propose
that this overexpression may be responsible, at least in part, to the survival and proliferations
of tumor cells, suggesting that this protein may function independently of its role within the
H/ACA RNP complex.
Finally, we were interested in correlating our data with clinical characteristics of patients as
well as the evolution of the disease. This analysis did not reveal any prognostic relevance for
the genes evaluated. The literature shows discordant results for hTERT expression, with
authors observing strong impact of telomerase activity on overall survival [22, 25, 39] while
others did not find any association [221, 276]. In addition, a recent report [37] did not find
impact of DKC1 expression on overall survival or progression free survival, but they observed
that cases with low DKC1 levels had a reduced survival following chemotherapy. There are no
reports about this matter for the remaining genes.
The current study is subject to a number of limitations. Our analysis was performed in a
retrospective cohort of CLL patients. Thus, as regards prognostic factors and outcome, the lack
in statistical significance could be due to the limited number of patients in our series. Addi-
tionally, we have not investigated protein expression, results that would increase the signifi-
cance of this study. Future analysis in larger cohorts will be useful to better define the
prognostic value of these genes as well as functional modifications.
Concluding, we have observed modifications in the expression profiles of GAR1, NOP10,
DKC1, hTERT and hTR genes in CLL patients. The correlation with prognostic factors of the
disease showed associations among DKC1, NHP2 and NPO10 mRNA levels with the presence
of two or more genetic alterations and of hTERT and DKC1 expression with short telomere
length, suggesting a role for these telomere associated genes in genomic instability and telo-
mere dysfunction in this pathology.
Supporting information
S1 Fig. Correlation among gene expression profiles of NHP2,GAR1 and NOP10.
(TIF)
S2 Fig. Heat map. Telomere-associated gene expression profiles in CLL patients.
(TIF)
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S1 Table. mRNA expression levels of telomere-associated genes and clinical and laboratory
features.
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